Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
Shinohara A, Ikeda M, Okuyama H, Kobayashi M, Funazaki H, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Ichida Y, Takahashi K, Okusaka T, Saitoh S. Shinohara A, et al. Among authors: takahashi h, takahashi k. Am J Clin Dermatol. 2015 Jun;16(3):221-9. doi: 10.1007/s40257-015-0116-x. Am J Clin Dermatol. 2015. PMID: 25687689
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Kan M, Imaoka H, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Umemoto K, Kimura G, Suzuki Y, Eguchi H, Otsuru T, Goda K, Ikeda M. Kan M, et al. Among authors: takahashi h. Cancer Chemother Pharmacol. 2020 Aug;86(2):203-210. doi: 10.1007/s00280-020-04110-3. Epub 2020 Jul 6. Cancer Chemother Pharmacol. 2020. PMID: 32632515 Clinical Trial.
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Tanaka H, Mitsunaga S, Kobayashi M, Funazaki H, Katayama S, Kuwahara A, Okuyama H, Takahashi H, Ohno I, Shimizu S, Sakamoto Y, Kondo S, Morizane C, Ueno H, Okusaka T, Ochiai A, Ikeda M. Tanaka H, et al. Among authors: takahashi h. Gan To Kagaku Ryoho. 2015 Mar;42(3):313-7. Gan To Kagaku Ryoho. 2015. PMID: 25812499 Japanese.
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Hasegawa H, Nomura S, Takahashi R, Yomoda S, Tsuchihara K, Kishino S, Esumi H. Ikeda M, et al. Among authors: takahashi h, takahashi r. Cancer Sci. 2016 Dec;107(12):1818-1824. doi: 10.1111/cas.13086. Epub 2016 Dec 19. Cancer Sci. 2016. PMID: 27685612 Free PMC article. Clinical Trial.
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M. Suzuki Y, et al. Among authors: takahashi h. J Gastroenterol. 2019 Mar;54(3):281-290. doi: 10.1007/s00535-018-1518-3. Epub 2018 Oct 8. J Gastroenterol. 2019. PMID: 30298469 Free PMC article. Clinical Trial.
Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.
Iizumi S, Kuchiba A, Okusaka T, Ikeda M, Sakamoto Y, Kondo S, Morizane C, Ueno H, Osame K, Mitsunaga S, Ohno I, Imaoka H, Hashimoto Y, Takahashi H, Sasaki M, Ohashi K. Iizumi S, et al. Among authors: takahashi h. Intern Med. 2019 Sep 1;58(17):2435-2441. doi: 10.2169/internalmedicine.2539-18. Epub 2019 Jun 7. Intern Med. 2019. PMID: 31178491 Free PMC article.
14,143 results
You have reached the last available page of results. Please see the User Guide for more information.